In this Q&A, Krishna Cheriath, VP and head of clinical research digital data and AI at Thermo Fisher Scientific, examines how ...
In today's ACT Brief, we examine why expanding governance layers slow digital modernization initiatives, how AI will augment ...
Angela Zubel, chief development officer at Debiopharm, framed 2026 as an implementation year—the moment when AI tools move from pilot programs into meaningful daily operations across drug development.
Pharma modernization initiatives stall not from lack of ambition but from expanding governance layers that distance ...
In today's ACT Brief, we explore why clinical trial diversity requires protocol redesign from the outset, the highest-impact ...
In this video interview, Krishna Cheriath, vice president and head of clinical research digital data and AI at Thermo Fisher ...
In a recent video interview with Applied Clinical Trials, Krishna Cheriath, vice president and head of clinical research ...
C.K Wang, MD General Manager of Oncology & Chief Medical Officer Verana Health C.K. Wang is the General Manager of Oncology ...
In today's ACT Brief, we examine how real-world data is being applied across oncology, ophthalmology, and other therapeutic ...
In part 3 of this three-part series, behavioral science reveals that clinical trial diversity cannot be achieved through last ...
Global RBM requires interoperable architectures across EDC, IRT, eCOA, labs, imaging, EHR, and safety systems, but inconsistent CDISC/HL7 FHIR adoption and proprietary APIs impede near–real-time ...
In today's ACT Brief, we examine the technical and operational challenges of implementing risk-based monitoring across global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results